Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
Immunic (Nasdaq: IMUX) reported Q1 2026 results and a corporate update. The company is running phase 3 ENSURE trials of vidofludimus calcium in relapsing MS, with top-line data expected by end 2026 and a planned U.S. NDA in mid-2027.
Immunic closed an oversubscribed private placement of up to $400 million, receiving $200 million upfront, and ended March 31, 2026 with $186.6 million in cash, expected to fund operations into late 2027. Q1 2026 net loss was $32.6 million on higher R&D and G&A expenses. The company appointed Michael A. Panzara as CMO, implemented a 1-for-10 reverse stock split, regained Nasdaq minimum bid compliance, and obtained a key European patent for vidofludimus calcium dosing regimens, expected to provide protection into 2038.
AI-generated analysis. Not financial advice.
Positive
- Oversubscribed private placement of up to $400 million, with $200 million received upfront
- Cash and cash equivalents of $186.6 million as of March 31, 2026
- Cash runway expected to fund operations into late 2027
- Phase 3 ENSURE RMS trials top-line data expected by end of 2026
- Planned U.S. NDA submission for RMS in mid-2027
- European patent on vidofludimus calcium dosing expected to protect into 2038, with potential SPC to 2043
- Regained compliance with Nasdaq minimum bid price listing requirement
- Appointed experienced neurology executive Michael A. Panzara as Chief Medical Officer
Negative
- Net loss increased to $32.6 million in Q1 2026 from $25.5 million
- R&D expenses rose to $25.6 million from $21.5 million year-over-year
- G&A expenses increased to $7.6 million from $5.3 million
- Other income (expense) declined to ($0.1) million from $1.2 million, mainly due to loss of grant income
- Implemented a 1-for-10 reverse stock split in April 2026
News Market Reaction – IMUX
On the day this news was published, IMUX gained 8.82%, reflecting a notable positive market reaction. Argus tracked a peak move of +17.6% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $181.22M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers showed mixed moves, with ATRA in the momentum scanner moving down 4.49% and ABOS up 3.23%, while IMUX’s move appears stock-specific rather than part of a unified sector trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Year-end 2025 results | Positive | +4.1% | Year-end 2025 results, $200M upfront financing and funding into late 2027. |
| Nov 13 | Q3 2025 earnings | Neutral | -6.2% | Q3 2025 results with positive CALLIPER data but ongoing net losses and liquidity gaps. |
| Aug 07 | Q2 2025 earnings | Neutral | -7.9% | Q2 2025 results, promising MS data and $70.1M financing but insufficient liquidity. |
| Nov 07 | Q3 2024 earnings | Positive | +0.0% | Q3 2024 update with positive ENSURE interim analysis and funding into Q3 2025. |
| Aug 08 | Q2 2024 earnings | Positive | +14.5% | Q2 2024 results, leadership additions and solid MS trial progress with $79.7M cash. |
Earnings and corporate updates have produced mixed reactions: some strong positive moves, but several instances where detailed clinical and financial progress coincided with negative or flat price action.
Over the last five earnings-related updates, Immunic has advanced its multiple sclerosis program and steadily extended its cash runway. Earlier releases highlighted an oversubscribed financing of $200 million upfront, progressing Phase 3 ENSURE trials with top-line RMS data targeted by year-end 2026, and plans for an NDA in mid-2027. Prior quarters showed net losses in the mid‑$20M range and limited liquidity, but also key CALLIPER and EMPhASIS data, new patents with protection into the 2040s, and incremental cash raises, setting the backdrop for today’s Q1 2026 results and corporate update.
Historical Comparison
In the past five earnings-style updates, IMUX averaged a 0.9% move, with a mix of strong rallies and notable selloffs, showing that earnings news has triggered variable reactions.
Earnings releases have tracked a progression from tight liquidity and modest cash balances to substantially improved funding, while maintaining timelines for Phase 3 ENSURE RMS data by year-end 2026, an NDA in mid-2027, and extended IP protection into the 2040s.
Regulatory & Risk Context
An effective S-3/A shelf dated April 30, 2026 registers up to 45,815,180 resale shares tied to pre-funded and common warrants from the February 2026 private placement. Immunic would not receive proceeds from resale transactions but could receive approximately $200.0M in aggregate if the warrants are exercised for cash.
Market Pulse Summary
The stock moved +8.8% in the session following this news. A strong positive reaction aligns with Immunic’s strengthened balance sheet and late-stage MS pipeline. The update combined Q1 2026 results, cash of $186.6 million funding operations into late 2027, and a previously completed private placement of up to $400 million. However, a sizable Q1 net loss of $32.6 million and an effective shelf for up to 45,815,180 resale shares mean dilution and warrant overhang could temper longer-term sustainability.
Key Terms
reverse stock split financial
nasdaq minimum bid price requirement regulatory
new drug application (nda) regulatory
supplementary protection certificate (spc) regulatory
epstein-barr virus (ebv) medical
magnetic resonance imaging (mri) medical
dihydroorotate dehydrogenase (dhodh) inhibition medical
private placement financial
AI-generated analysis. Not financial advice.
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –
– Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 –
– Raised
"We are fast approaching a highly pivotal juncture, with the anticipated top-line data readout of the twin phase 3 ENSURE trials of our lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS), expected by the end of 2026," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "In anticipation, we strengthened our leadership team with the recent appointment of Dr. Michael A. Panzara as Chief Medical Officer. Mike brings deep expertise in neurology and a proven track record of advancing multiple sclerosis (MS) therapies through late-stage clinical development and global regulatory approvals. Additionally, we enhanced our Board of Directors with the appointment of Jon Congleton, who has nearly four decades of biopharmaceutical leadership experience. Earlier in the quarter, Simona Skerjanec, M.Pharm, M.B.A., who joined Immunic's Board of Directors in July 2024, has been elevated to interim Chairperson of the Board and Thor Nagel, Principal at BVF Partners L.P., has been appointed as a member of the Board. Together, these key appointments are intended to best position the company for successful execution of our late-stage development priorities and prepare for potential commercialization."
Dr. Vitt continued, "As important, in February, we closed an oversubscribed private placement financing of up to
Jason Tardio, President and Chief Operating Officer of Immunic, added, "We believe vidofludimus calcium has the potential to offer a transformative approach to disease modification in MS. Unlike currently available oral therapies that primarily target inflammatory pathways, vidofludimus calcium is designed to deliver both direct neuroprotective effects through Nurr1 activation and anti-inflammatory activity via selective DHODH inhibition. In clinical trials to date, vidofludimus calcium has demonstrated a favorable safety and tolerability profile. Taken together, these attributes may support a compelling benefit-risk profile in the global MS market, which is projected to exceed
First Quarter 2026 and Subsequent Highlights
- April 2026: Appointed accomplished biopharmaceutical executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, to lead the company's development organization, including clinical development, medical affairs, and regulatory affairs. Dr. Panzara succeeds Andreas Muehler, M.D., M.B.A., who will continue to support the company as a consultant.
- April 2026: Effected 1-for-10 reverse stock split of the outstanding shares of common stock as of April 27, 2026.
- April 2026: Regained compliance with Nasdaq minimum bid price requirement (Rule 5550(a)(2)) for continued listing, following receipt of a written notice on March 27, 2026.
- March 2026: Appointed Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to the Board of Directors.
- March 2026: Announced grant of a key European patent from the European Patent Office (EPO) directed to label-relevant dosing regimens of vidofludimus calcium. The patent is expected to provide protection into 2038 and may be eligible for a Supplementary Protection Certificate (SPC), which could extend market exclusivity potentially into 2043. This patent was previously granted by the United States Patent and Trademark Office (USPTO) in 2023.
- February 2026: Completed an oversubscribed private placement financing of up to
$400 million $200 million - Elevated Simona Skerjanec, former SVP, Global Head of Neuroscience and Rare Diseases at Roche, to Interim Chairperson of the Board of Directors. Dr. Duane Nash, former Chairman, remains a member of the Board. Appointed Thor Nagel, Principal at BVF Partners L.P., to the Board. Plans underway for further Board refreshment to support the company's evolution into a commercial-stage organization.
- Initiated search for a new Chief Executive Officer with deep commercial expertise in neurology to lead Immunic into its next stage of growth and commercialization. Subsequently, Dr. Vitt will return to his roots and transition to a new senior executive role focused on scientific strategy and portfolio advancement, while remaining on the Board.
- February 2026: Presented additional data from the phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS at the ACTRIMS Forum 2026 in
San Diego, California . The findings, presented in two poster presentations, provide additional evidence of vidofludimus calcium's effects on key biological drivers of disease progression, including antiviral immune responses linked to Epstein-Barr virus (EBV) and magnetic resonance imaging (MRI) markers of both acute-focal and chronic-compartmentalized inflammation. The findings further reinforce Immunic's belief that vidofludimus calcium has the potential to address underlying mechanisms of disease progression in MS patients.
Anticipated Clinical Milestones
- Vidofludimus calcium in MS:
- Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials in RMS is expected by the end of 2026. Subsequently, Immunic plans to submit an NDA in
the United States in mid-2027, with a targeted potential regulatory approval date in 2028. - Initiation of a phase 3 clinical program in PPMS is expected later this year and is estimated to take approximately 3.5 to 4 years to complete.
- Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials in RMS is expected by the end of 2026. Subsequently, Immunic plans to submit an NDA in
- IMU-856: The company is currently exploring strategic alternatives for the IMU-856 program and is open to discussing potential financing, licensing or partnering options with interested parties.
Financial and Operating Results
- Research and Development (R&D) Expenses were
$25.6 million $21.5 million $4.1 million $2.9 million $1.0 million $0.7 million $0.2 million - General and Administrative (G&A) Expenses were
$7.6 million $5.3 million $2.3 million $2.0 million $1.8 million $0.2 million $0.2 million $0.1 million - Interest Income was
$0.8 million $0.2 million $0.6 million - Other Income (Expense) was
( for the three months ended March 31, 2026, as compared to$0.1) million $1.2 million $1.3 million $1.1 million $0.2 million - Net Loss for the three months ended March 31, 2026, was approximately
$32.6 million $1.08 $25.5 million $2.51 - Cash and Cash Equivalents as of March 31, 2026 were
$186.6 million
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
Financials
Immunic, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) | ||||
Three Months Ended March 31, | ||||
2026 | 2025 | |||
Operating expenses: | ||||
Research and development | $ 25,626 | $ 21,533 | ||
General and administrative | 7,609 | 5,292 | ||
Total operating expenses | 33,235 | 26,825 | ||
Loss from operations | (33,235) | (26,825) | ||
Other income: | ||||
Interest income | 760 | 183 | ||
Other income (expense), net | (113) | 1,169 | ||
Total other income | 647 | 1,352 | ||
Net loss | $ (32,588) | $ (25,473) | ||
Net loss per share, basic and diluted | $ (1.08) | $ (2.51) | ||
Weighted-average common shares outstanding, basic and diluted | 30,136,324 | 10,134,443 | ||
Immunic, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) | ||||
March 31, | December 31, | |||
(Unaudited) | ||||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 186,629 | $ 15,483 | ||
Prepaid expenses and other current assets | 2,130 | 7,386 | ||
Total current assets | 188,759 | 22,869 | ||
Property and equipment, net | 566 | 608 | ||
Right-of-use assets, net | 417 | 575 | ||
Total assets | $ 189,742 | $ 24,052 | ||
Liabilities and Stockholders' Equity (Deficit) | ||||
Current liabilities: | ||||
Accounts payable | $ 11,011 | $ 10,138 | ||
Accrued expenses | 22,432 | 18,645 | ||
Other current liabilities | 4,920 | 1,835 | ||
Total current liabilities | 38,363 | 30,618 | ||
Long-term liabilities | ||||
Operating lease liabilities | 146 | 107 | ||
Total long-term liabilities | 146 | 107 | ||
Total liabilities | 38,509 | 30,725 | ||
Commitments and contingencies | ||||
Stockholders' equity (deficit): | ||||
Preferred stock, | — | — | ||
Common stock, | 11 | 9 | ||
Additional paid-in capital | 789,324 | 599,241 | ||
Accumulated other comprehensive income | 3,057 | 2,648 | ||
Accumulated deficit | (641,159) | (608,571) | ||
Total stockholders' equity (deficit) | 151,233 | (6,673) | ||
Total liabilities and stockholders' equity (deficit) | $ 189,742 | $ 24,052 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302769899.html
SOURCE Immunic, Inc.